Abstract
Background: MASK-air® is an app that supports allergic rhinitis patients in disease control. Users register daily allergy symptoms and their impact on activities using visual analog scales (VASs). We aimed to assess the concurrent validity, reliability, and responsiveness of these daily VASs. Methods: Daily monitoring VAS data were assessed in MASK-air® users with allergic rhinitis. Concurrent validity was assessed by correlating daily VAS values with those of the EuroQol-5 Dimensions (EQ-5D) VAS, the Control of Allergic Rhinitis and Asthma Test (CARAT) score, and the Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire (work and activity impairment scores). Intra-rater reliability was assessed in users providing multiple daily VASs within the same day. Test–retest reliability was tested in clinically stable users, as defined by the EQ-5D VAS, CARAT, or “VAS Work” (i.e., VAS assessing the impact of allergy on work). Responsiveness was determined in users with two consecutive measurements of EQ-5D-VAS or “VAS Work” indicating clinical change. Results: A total of 17,780 MASK-air® users, with 317,176 VAS days, were assessed. Concurrent validity was moderate–high (Spearman correlation coefficient range: 0.437–0.716). Intra-rater reliability intraclass correlation coefficients (ICCs) ranged between 0.870 (VAS assessing global allergy symptoms) and 0.937 (VAS assessing allergy symptoms on sleep). Test–retest reliability ICCs ranged between 0.604 and 0.878—“VAS Work” and “VAS asthma” presented the highest ICCs. Moderate/large responsiveness effect sizes were observed—the sleep VAS was associated with lower responsiveness, while the global allergy symptoms VAS demonstrated higher responsiveness. Conclusion: In MASK-air®, daily monitoring VASs have high intra-rater reliability and moderate–high validity, reliability, and responsiveness, pointing to a reliable measure of symptom loads.
Original language | English |
---|---|
Article number | e12062 |
Number of pages | 15 |
Journal | Clinical and Translational Allergy |
Volume | 11 |
Issue number | 7 |
DOIs | |
Publication status | Published - Aug 2021 |
Keywords
- allergic rhinitis
- mobile health
- reliability
- responsiveness
- visual analog scales
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical and Translational Allergy, Vol. 11, No. 7, e12062, 08.2021.
Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air®
AU - Sousa-Pinto, Bernardo
AU - Eklund, Patrik
AU - Pfaar, Oliver
AU - Klimek, Ludger
AU - Zuberbier, Torsten
AU - Czarlewski, Wienczyslawa
AU - Bédard, Annabelle
AU - Bindslev-Jensen, Carsten
AU - Bedbrook, Anna
AU - Bosnic-Anticevich, Sinthia
AU - Brussino, Luisa
AU - Cardona, Victoria
AU - Cruz, Alvaro A.
AU - de Vries, Govert
AU - Devillier, Philippe
AU - Fokkens, Wytske J.
AU - Fuentes-Pérez, José Miguel
AU - Gemicioğlu, Bilun
AU - Haahtela, Tari
AU - Huerta-Villalobos, Yunen Rocío
AU - Ivancevich, Juan Carlos
AU - Kull, Inger
AU - Kuna, Piotr
AU - Kvedariene, Violeta
AU - Larenas Linnemann, Désirée E.
AU - Laune, Daniel
AU - Makris, Michael
AU - Melén, Erik
AU - Morais-Almeida, Mário
AU - Mösges, Ralph
AU - Mullol, Joaquim
AU - O'Hehir, Robyn E.
AU - Papadopoulos, Nikolaos G.
AU - Pereira, Ana Margarida
AU - Prokopakis, Emmanuel P.
AU - Psarros, Fotis
AU - Regateiro, Frederico S.
AU - Reitsma, Sietze
AU - Samolinski, Boleslaw
AU - Scichilone, Nicola
AU - da Silva, Jane
AU - Stellato, Cristiana
AU - Todo-Bom, Ana
AU - Tomazic, Peter Valentin
AU - Salmi, Sanna Toppila
AU - Valero, Antonio
AU - Valiulis, Arunas
AU - Valovirta, Erkka
AU - van Eerd, Michiel
AU - Ventura, Maria Teresa
AU - Yorgancioglu, Arzu
AU - Basagaña, Xavier
AU - Antó, Josep M.
AU - Bousquet, Jean
AU - Fonseca, João Almeida
N1 - Funding Information: The study was funded by ARIA. Funding Information: Sinthia Bosnic‐Anticevich reports grants from TEVA and personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. Jean Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, and personal fees from Purina. Victoria Cardona reports personal fees from ALK, Allergy Therapeutics, LETI, Thermofisher, Merck, Astrazeneca, and GSK. Alvaro A Cruz reports grants and personal fees from GlaxoSmithKline, personal fees from Sanofi, AstraZeneca, Novartis, Chiesi, Boehringer Ingelheim, Mylan, and Eurofarma. Philippe Devillier reports personal fees from Mylan. Bilun Gemicioğlu reports grants from AstraZeneca, MSD, GSK, Deva, Novartis, and Abdi Ibrahim. Tari Haahtela reports personal fees from GSK, Mundipharma, Orion Pharma, Sanofi, Juan Carlos Ivancevich reports personal fees from Sanofi, Faes Farma, Laboratorios Casasco, Abbott, Ludger Klimek reports grants and personal fees from Allergopharma, LETI Pharma, MEDA/Mylan, and Sanofi, personal fees from Allergy Therapeut, Casssela med, and HAL Allergie, grants from ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotk, and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, and EAACI. Piotr Kuna reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, Boehringer Ingelheim, GSK, HAL Allergy, Lekam, Mylan, Novartis, and Teva. Désirée Larenas Linnemann reports personal fees from Allakos, Amstrong, Astrazeneca, DBV Technologies, Grunenthal, GSK, Mylan, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, and Gossamer, grants from Sanofi, Astrazeneca, Novartis, Circassia, UCB, GSK, TEVA, and Purina Institute. Michael Makris reports personal fees from Novartis, AstraZeneca, GSK, Chiesi, Menarini, Sanofi Genzyme, and Pfizer. Joaquin Mullol reports personal fees and other from SANOFI‐GENZYME & REGENERON, Genentech‐Roche & NOVARTIS, grants and personal fees from VIATRIS (MEDA‐MYLAN Pharma) and URIACH Group, and personal fees from Mitsubishi‐Tanabe, Menarini, UCB, AstraZeneca, and GSK. Oliver Pfaar reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Anergis S.A., ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, and Glaxo Smith Kline, grants from Biomay, Circassia, Pohl‐Boskamp, and Inmunotek S.L., and personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GALEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, and Paul‐Martini‐Stiftung (PMS). Nikolaos G. Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, and Boehringer Ingelheim and grants from Gerolymatos International SA, and Capricare. Boleslaw Samolinski reports personal fees from Allergopharma, Polpharma, Viatris, TEVA, ADAMED, patient ombudsman, and Polish Allergology Society, grants from AstraZeneca, National Health Programme, and grants and personal fees from AstraZeneca. Ana Todo‐Bom reports grants and personal fees from AstraZeneca, GSK (GlaxoSmithKline), Novartis, Sanofi, Teva, and Mundipharma, personal fees from Bial, and grants from Leti. Torsten Zuberbier reports personal fees from Bayer Health Care, FAES, Novartis, Henkel, Novartis, from Henkel, AstraZeneca, AbbVie Fee for talk, ALK Fee for talk, Almirall Fee for talk, Astellas Fee for talk, Bayer Health Care Fee for talk, Bencard Fee for talk, Berlin Chemie Fee for talk, FAES Fee for talk, HAL Fee for talk, Leti Fee for talk, Meda Fee for talk, Menarini Fee for talk, Merck Fee for talk, MSD Fee for talk, Novartis Fee for talk, Pfizer Fee for talk, Sanofi Fee for talk, Stallergenes Fee for talk, Takeda Fee for talk, Teva Fee for talk, UCB Fee for talk, Henkel Fee for talk, Kryolan Fee for talk, and L'Oréal Fee for talk. 2 Publisher Copyright: © 2021 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - Background: MASK-air® is an app that supports allergic rhinitis patients in disease control. Users register daily allergy symptoms and their impact on activities using visual analog scales (VASs). We aimed to assess the concurrent validity, reliability, and responsiveness of these daily VASs. Methods: Daily monitoring VAS data were assessed in MASK-air® users with allergic rhinitis. Concurrent validity was assessed by correlating daily VAS values with those of the EuroQol-5 Dimensions (EQ-5D) VAS, the Control of Allergic Rhinitis and Asthma Test (CARAT) score, and the Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire (work and activity impairment scores). Intra-rater reliability was assessed in users providing multiple daily VASs within the same day. Test–retest reliability was tested in clinically stable users, as defined by the EQ-5D VAS, CARAT, or “VAS Work” (i.e., VAS assessing the impact of allergy on work). Responsiveness was determined in users with two consecutive measurements of EQ-5D-VAS or “VAS Work” indicating clinical change. Results: A total of 17,780 MASK-air® users, with 317,176 VAS days, were assessed. Concurrent validity was moderate–high (Spearman correlation coefficient range: 0.437–0.716). Intra-rater reliability intraclass correlation coefficients (ICCs) ranged between 0.870 (VAS assessing global allergy symptoms) and 0.937 (VAS assessing allergy symptoms on sleep). Test–retest reliability ICCs ranged between 0.604 and 0.878—“VAS Work” and “VAS asthma” presented the highest ICCs. Moderate/large responsiveness effect sizes were observed—the sleep VAS was associated with lower responsiveness, while the global allergy symptoms VAS demonstrated higher responsiveness. Conclusion: In MASK-air®, daily monitoring VASs have high intra-rater reliability and moderate–high validity, reliability, and responsiveness, pointing to a reliable measure of symptom loads.
AB - Background: MASK-air® is an app that supports allergic rhinitis patients in disease control. Users register daily allergy symptoms and their impact on activities using visual analog scales (VASs). We aimed to assess the concurrent validity, reliability, and responsiveness of these daily VASs. Methods: Daily monitoring VAS data were assessed in MASK-air® users with allergic rhinitis. Concurrent validity was assessed by correlating daily VAS values with those of the EuroQol-5 Dimensions (EQ-5D) VAS, the Control of Allergic Rhinitis and Asthma Test (CARAT) score, and the Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire (work and activity impairment scores). Intra-rater reliability was assessed in users providing multiple daily VASs within the same day. Test–retest reliability was tested in clinically stable users, as defined by the EQ-5D VAS, CARAT, or “VAS Work” (i.e., VAS assessing the impact of allergy on work). Responsiveness was determined in users with two consecutive measurements of EQ-5D-VAS or “VAS Work” indicating clinical change. Results: A total of 17,780 MASK-air® users, with 317,176 VAS days, were assessed. Concurrent validity was moderate–high (Spearman correlation coefficient range: 0.437–0.716). Intra-rater reliability intraclass correlation coefficients (ICCs) ranged between 0.870 (VAS assessing global allergy symptoms) and 0.937 (VAS assessing allergy symptoms on sleep). Test–retest reliability ICCs ranged between 0.604 and 0.878—“VAS Work” and “VAS asthma” presented the highest ICCs. Moderate/large responsiveness effect sizes were observed—the sleep VAS was associated with lower responsiveness, while the global allergy symptoms VAS demonstrated higher responsiveness. Conclusion: In MASK-air®, daily monitoring VASs have high intra-rater reliability and moderate–high validity, reliability, and responsiveness, pointing to a reliable measure of symptom loads.
KW - allergic rhinitis
KW - mobile health
KW - reliability
KW - responsiveness
KW - visual analog scales
UR - http://www.scopus.com/inward/record.url?scp=85115860874&partnerID=8YFLogxK
U2 - 10.1002/clt2.12062
DO - 10.1002/clt2.12062
M3 - Review Article
AN - SCOPUS:85115860874
SN - 2045-7022
VL - 11
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 7
M1 - e12062
ER -